Wednesday February 13th,2013 : « Production of AAV vectors in Baculoviruses » Dr Robert M. Kotin, National Institutes of Health (NIH), Laboratory of Molecular Virology and Gene Therapy, Bethesda, US.
This year’s Telethon will remain the challenge of all challenges: the challenge of donors and volunteers in the face of crisis, the challenge of researchers and families in the face of disease … Together, we have tackled them, with determination and courage, all united by the same desire: win! The counter of Telethon 2012 stopped … [Read more]
Gene therapies advance, but some see manufacturing challenges
“Gene therapy has traveled a long and winding road to the clinic. The field famously hit a major roadblock 13 years ago when the teenager Jesse Gelsinger suffered a fatal immune reaction in response to a gene therapy product designed to correct his rare liver disease, leading to a perception…”
Author : Elie Dolgin
Non-profit Drugs: a first in France!
Thanks to a new decree, “Drugs for innovative therapy”, Genethon, the AFM-Telethon laboratory, will be able to commercialize products from its research. A first in the non-profit arena.
Author(s) : Handicap.fr – E.Dal’Secco http://www.handicap.fr
Read the article [PDF – 18,7 ko]
“Drugs for innovative therapies”: a new step for AFM-Telethon and its Genethon laboratory.
Read the article [PDF – 21,4 ko]